Patient Engagement—The Benefits Without the Risks
22 April, 2020Everything you need to know about the Federal Anti-Kickback Statute and the Beneficiary Inducement Statute and how it affects your patient engagement program.
Adoptive Cell Therapy — Hope or Hype?
19 April, 2020The therapeutic field of adoptive cell therapy (ACT) in cancer has expanded dramatically in recent years, both in investment activity and technology proliferation. Tune in to our web panel discussion to find out what experts think is in store for this exciting field.
Best Practices for Maintaining a Trial Master File
30 March, 2020We recently sat with the experts at LMK Clinical Research Consulting to get their perspective on electronic Trial Master File (eTMF) challenges and best practices.
Microbiomes — Hope OR Hype?
20 March, 2020In light of our March 2017 web panel discussion, we sat down with Dr. Ravi Kiron, Managing Partner at Biopharm Strategy Advisors and moderator of the webinar, to find out whether this area could revolutionize the healthcare industry of the future or whether we are treading on dangerous ground that we know little about.
Why Life Science Companies Fail + The Fix
16 March, 2020In this webinar, our speaker, Lucia Mokres, the Founder and Principal of Araneae Biotech Consulting, will examine the complexities of this scientific founder knowledge gap and explore why even when aware of this knowledge gap many founders are overwhelmed, resistant, unfamiliar, unaware, and unable to...
Precision Medicine and CNS Disorders
15 March, 2020Precision medicine is a move away from a one-size-fits-all approach toward an approach with the goal to target the right treatments to the right patients at the right time.
The Top 10 Biopharma Deals of 2019
20 February, 2020Following are the top ten biopharma deals of 2019. For a comprehensive picture of all the prominent deals of 2019, download our 2019 Biopharma Partnering and M&A Year in Review Infographic.
Bispecific Antibodies: Are Two Really Better Than One?
25 January, 2020In advance of the web panel discussion, we sat down with Linda Pullan to learn a little more about bispecifics and what you can expect to learn from the discussion.
TAntibody-Drug Conjugates (ADC)
24 January, 2020The Promise and Challenges of Antibody-Drug Conjugates (ADC) Antibody-drug conjugates, or ADCs, are a new class of highly potent biopharmaceutical drug that can ferry drugs into cancer cells while...